First Patient Dosed in Phase 3 Trial Testing Tyvyt as First-line Therapy for Esophageal Cancer
First Esophageal Cancer patient is dosed in Phase 3 clinical trial using immune checkpoint inhibitor Tyvyt (sintilimab injection), in [...]
Esophageal Cancer Genome
ECAN’s President and CEO Mindy Mintz Mordecai recently had the opportunity to interview Dr. Adam Bass, co-chair of the [...]